摘要
目的:探讨参七脑康胶囊联合神经节苷脂钠注射液对急性颅脑损伤患者临床效果、神经细胞因子及可溶性尿激酶型纤溶酶原激活物受体(suPAR)、类胰岛素生长因子Ⅱ(IGF-Ⅱ)、泛素羧基末端水解酶1(UCH-L1)水平的影响。方法:选取2020年6月-2022年6月佳木斯市中心医院收治的116例急性颅脑损伤患者,按照随机数字表法将患者分为对照组和观察组,各58例。对照组以神经节苷脂钠注射液治疗,观察组在对照组的基础上加用参七脑康胶囊。比较两组临床疗效、症状评分、神经细胞因子水平、suPAR、IGF-Ⅱ、UCH-L1水平、治疗安全性等。结果:观察组总有效率为91.38%(53/58),高于对照组的74.14%(43/58)(P<0.05)。治疗后,观察组神经功能缺损评分(NIHSS)低于对照组,格拉斯哥昏迷指数(GCS)评分高于对照组(P<0.05)。治疗后,观察组神经细胞因子神经元特异性烯醇化酶(NSE)、髓鞘碱性蛋白(MBP)、中枢神经特异蛋白(S100-β)水平均低于对照组(P<0.05)。治疗后观察组suPAR、IGF-Ⅱ、UCH-L1水平均低于对照组(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:参七脑康胶囊联合神经节苷脂钠注射液对急性颅脑损伤的疗效显著,能够改善患者的神经认知功能评分,抑制神经细胞因子及suPAR、IGF-Ⅱ、UCH-L1水平的表达,治疗安全性较高,可临床推荐。
Objective:To study the effect of Shenqi Naokang Capsules combined with Ganglioside Sodium Injection on the clinical efficacy,the levels of neurocytokines,soluble urokinase plasminogen activator receptor(suPAR),insulin-like growth factorⅡ(IGF-Ⅱ)and ubiquitin carboxyl terminal hydrolyzase 1(UCH-L1)in patients with acute brain injury.Method:A total of 116 patients with acute brain injury admitted to Jiamusi Central Hospital from June 2020 to June 2022 were selected,they were divided into control group and observation group according to random number table method,with 58 cases in each group.The control group was treated with Ganglioside Sodium Injection,and the observation group was treated with Shenqi Naokang Capsules on the basis of the control group.The clinical efficacy,symptom scores,neurocytokine levels,suPAR,IGF-Ⅱ,UCH-L1 levels and treatment safety of the two groups were compared.Result:The total effective rate in the observation group was 91.38%(53/58),which was higher than 74.14%(43/58)in the control group(P<0.05).After treatment,neurological deficit score(NIHSS)in the observation group was lower than that in the control group,and the score of Glasgow coma scale(GCS)in the observation group was higher than that in the control group(P<0.05).After treatment,neurocytokines neuron specific enolase(NSE),myelin basic protein(MBP),central nerve specific protein(S100-β)in the observation group were lower than those in the control group(P<0.05).After treatment,the levels of suPAR,IGF-Ⅱand UCH-L1 in the observation group were lower than those in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Shenqi Naokang Capsules combined with Ganglioside Sodium Injection has significant effect on acute brain injury,it can improve the neurocognitive function scores of patients,inhibit the expression of neurocytokines and the levels of suPAR,IGF-Ⅱand UCH-L1,is safe and can be recommended clinically.
作者
崔博
CUI Bo(Jiamusi Central Hospital,Heilongjiang Province,Jiamusi 154002,China)
出处
《中国医学创新》
CAS
2023年第9期36-40,共5页
Medical Innovation of China
